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Purpose: Tumor marker concentrations in a given specimen measured by different 
analyzers vary according to assay methods, epitopes for antibodies used, and re-
agent specificities. Although great effort in quality assessment has been instituted, 
discrepancies among results from different analyzers are still present. We evaluated 
the assay performance of the UniCelTM DxI 800 automated analyzer in measuring 
the alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), carbohydrate anti-
gen (CA) 125, CA 15-3 and CA 19-9 tumor markers. Materials and Methods: 
The linearity and precision performance of the five tumor marker assays were 
evaluated, and concentrations of the respective markers as measured by DxI were 
compared to those measured by other conventional analyzers (ADVIA CentaurTM 
and VitrosTM ECi) using 200 specimens collected from 100 healthy persons and 
100 patients with respective cancers. Results: The linear fits for all five tumor 
markers were statistically acceptable (F=4648 for AFP, F=15846 for CEA, F=6445 
for CA 125, F=2285 for CA 15-3, F=7459 for CA 19-9; p<0.0001 for all). The im-
precision of each tumor marker assay was less than 5% coefficient of variation, ex-
cept for low and high concentrations of AFP. The results from UniCelTM DxI 800 
were highly correlated with those from other analyzers. Conclusion: Our results 
demonstrate that UniCelTM DxI 800 has good linearity and precision performance 
for the tumor markers assayed in this study. However, there were discrepancies be-
tween assaying methods. Efforts to standardize tumor marker assays should be un-
dertaken, and the redetermination of cut-off levels is necessary when developing 
methods of analyzing tumor markers.
Key Words:   Alpha-fetoprotein (AFP), CA 125, CA 15-3, CA 19-9, carcinoem-
bryonic antigen (CEA), tumor markers
INTRODUCTION
Tumor markers are substances produced by tumors or by the host in response to 
the presence of a tumor, and are used to differentiate a tumor from normal tissue. 
Such substances are found in cells, tissues, or body fluids and can be measured 
qualitatively or quantitatively by chemical, immunological, or molecular biologi-
cal methods.1 For many malignancies, the determination of serum tumor markers 
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the use of nonisotopic immunoassays and the institution of 
quality assessment efforts, discrepancies still arise among 
results from different analyzers. Accordingly, standardized 
reagents for tumor marker assays are needed to ensure the 
reliability of the results from different assays, and the stan-
dardization thereof is also important for commutability 
among results from different assays in order to deal with in-
creased patient mobility between hospitals.
With the increased incidence and prevalence of cancers, 
the workload on tumor marker assays in clinical laborato-
ries has also increased. The UniCelTM DxI 800 Access Im-
munoassay System (DxI) is an automated instrument that 
can handle a large volume of various test items with high 
throughput, and only a few studies have tested the perfor-
mance characteristics of this analyzer so far.14-16 In this study, 
we aimed to evaluate the analytical performance of this im-
munoassay analyzer in measuring five tumor markers 
(AFP, CEA, CA 15-3, CA 125, and CA 19-9).
MATERIALS AND METHODS
　　　
Linearity and precision performance of the UniCelTM DxI 
800 Access Immunoassay System (Beckman Coulter Inc., 
Brea, CA, USA) in measuring the five aforementioned tumor 
markers were evaluated. The results of the respective tumor 
marker levels as measured by DxI were compared with AFP, 
CEA, and CA 125 levels measured by the ADVIA CentaurTM 
XP Immunoassay System (Centaur) (Siemens Healthcare 
Diagnostics Inc., Deerfield, IL, USA) and with CA 15-3 and 
CA 19-9 concentrations measured by the VitrosTM ECi Im-
munodiagnostic System (ECi) (Ortho Clinical Diagnostics 
Ltd., Auckland, New Zealand). All assays were performed 
according to the manufacturers’ instructions. 
Precision performance evaluation
Imprecision of the assays by DxI was assessed based on 
guidelines from the Clinical and Laboratory Standards In-
stitute (CLSI) document EP4-A2, using commercially 
available quality control materials of three levels (MAS T-
Marker; Medical Analysis Systems, Camarillo, CA, USA) 
and pooled sera for the respective markers. Two daily runs 
of duplicate testing were conducted per day for 20 days, 
with a minimum of 2 hours between runs.
Linearity of the assays
Tests for validating the linearity of the assays were per-
plays an important role in clinical research and diagnosis. 
Currently, tumor markers are widely used during therapy in 
order to perceive an indication of response to therapy and 
to distinguish between remission and progression. Tumor 
markers also provide important information towards recog-
nizing recurrences and metastases at an early point in dis-
ease progression.2-7
Carcinoembryonic antigen (CEA) is a highly glycosylat-
ed cell surface glycoprotein with a molecular weight of 
150-300 kDa, which can be detected at high levels in colon 
epithelial cells during embryonic development. Levels of 
CEA are significantly lower in adult colon tissue, but be-
come elevated when inflammation or tumors arise in any 
endodermal tissue, including that of the gastrointestinal 
tract, respiratory tract, pancreas, and breast.1,8-11 Alpha-feto-
protein (AFP) is a glycoprotein with a molecular mass of 
70 kDa, which is synthesized in large quantities during em-
bryonic development of the fetal yolk sac and liver, and it 
can be used as a marker for hepatocellular or germ cell 
(nonseminoma) carcinoma, except in pregnant individu-
als.1,7 Carbohydrate antigen 15-3 (CA 15-3) was initially 
detected by the murine monoclonal antibody (MAb) DF3, 
prepared against the human breast carcinoma cell line 
MCF-7. The circulating DF3-reactive antigen is a heteroge-
nous molecule with a molecular mass of 300 to 450 kDa. In 
previous studies, CA 15-3 was useful in monitoring therapy 
and predicting the progression of metastatic breast can-
cer.1,2,12 The carbohydrate antigen 125 (CA 125) is a glyco-
protein with about a 200 kDa molecular weight which is 
recognized by the monoclonal antibody OC 125, and mea-
surement of the CA 125 antigen can aid in the management 
of patients diagnosed with ovarian cancer.1,13 Carbohydrate 
antigen 19-9 (CA 19-9) is a marker for both colorectal and 
pancreatic carcinoma, and is used in monitoring patients 
with these cancers during palliative chemotherapy in con-
junction with imaging tests.1,4,10
Early detection of cancer offers the best chance for a cure. 
Unfortunately, most cancers do not produce symptoms until 
carcinogenesis has progressed; however, most tumor mark-
ers are used to monitor treatment responses and recurrences 
of cancers. Therefore, more sensitive, specific, and repro-
ducible detection methods would be helpful for managing 
patients with cancers. However, the concentration of a tu-
mor marker in a given specimen, determined with assays 
from different manufacturers, can vary due to differences in 
assay methods, types of antibodies and epitopes used, and 
reagent specificity. Although precision has improved from 
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yse-it Software Ltd., Leeds, UK). Comparisons between as-
says were estimated with regression equations calculated 
by Passing and Bablok regression analysis and with the 
mean-difference plots of Bland and Altman.17-19
 
RESULTS
 
Precision performances
The within-run, between-run, between-day, and total preci-
sion performances of five tumor markers are summarized 
in Table 1. Within-run imprecision ranged from 1.7% to 
4.1% coefficient of variation (CV), and between-run and 
between-day imprecision was between 0.5% and 3.6% CV 
and between 0.0% and 3.4% CV, respectively. Total impre-
cision ranged from 2.8% to 5.5% CV for all assessed levels 
of tumor markers.
Linearity of the assays
Linearity of the five tumor marker assays (CEA, AFP, CA 
15-3, CA 125, and CA 19-9) were evaluated with 6 levels of 
serum samples prepared from mixing high and low pooled 
sera, of which the concentrations ranged from 951.41 to 0.80 
μg/L for CEA, from 2092.91 to 1.86 μg/L for AFP, from 
formed based on the CLSI document EP6-A. Pooled serum 
samples with high and low concentrations were mixed to 
make six equally spaced samples for their respective tumor 
markers. Four intermediate concentration pools were mixed 
as follows: 0.8 Low (L)+0.2 High (H), 0.6 L+0.4 H, 0.4 
L+0.6 H, and 0.2 L+0.8 H. All pools were assayed in qua-
druplicate for their respective markers, and the mean was 
compared with the expected values.
Method comparison
Correlation between the levels of tumor markers as mea-
sured by DxI and Centaur or ECi were evaluated in 200 
specimens for respective tumor markers (total 2000 tests 
with 1000 samples). All sera, which were requested for tu-
mor marker testing, were collected and assayed for the re-
spective tumor markers with DxI and other comparative in-
struments on the same day. The samples with measured 
concentrations over the analytical measurement range were 
re-tested after dilution according to the manufacturers’ in-
structions.
Statistical analysis
All statistical analyses were performed using the Analyse-it 
Method Evaluation Edition version 2.22 software (Anal-
Table 1. Precision Performances of UniCelTM DxI 800 in Measuring Five Tumor Markers
Assayed materials Mean concentration*
Coefficient of variation (%)
Within-run Between-run Between-day Total
CEA level 1     1.25 2.5 3.6 1.1 4.5
CEA level 2   10.52 1.8 1.9 2.7 3.8
CEA level 3   48.13 2.7 2.3 2.5 4.4
CEA pooled serum     3.39 2.1 2.9 0.9 3.7
AFP level 1     4.70 2.9 2.9 3.4 5.4
AFP level 2   22.53 3.0 3.4 2.1 5.0
AFP level 3 100.07 4.1 2.9 2.3 5.5
AFP pooled serum   88.91 2.5 4.1 0.0 4.3
CA 15-3 level 1     5.02 3.5 2.2 2.5 4.9
CA 15-3 level 2   20.00 2.9 2.7 1.6 4.2
CA 15-3 level 3   33.38 3.1 3.1 0.0 4.4
CA 15-3 pooled serum     8.49 3.9 1.9 0.3 4.3
CA 125 level 1   15.60 2.5 2.6 0.0 3.6
CA 125 level 2   34.00 2.8 0.5 0.0 2.8
CA 125 level 3 117.72 1.7 1.6 1.8 3.0
CA 125 pooled serum   23.48 2.7 1.0 1.2 3.1
CA 19-9 level 1     8.53 2.8 1.4 3.1 4.4
CA 19-9 level 2   32.33 1.9 2.7 2.2 3.9
CA 19-9 level 3 146.71 1.8 2.7 1.7 3.7
CA 19-9 pooled serum   14.85 2.5 2.3 2.3 4.1
CEA, carcinoembryonic antigen; AFP, alpha-fetoprotein; CA, carbohydrate antigen.
*Units are µg/L for CEA and AFP, and kU/L for CA 15-3, CA 125, and CA 19-9. 
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Comparison between the assays
Comparison of the assays performed by DxI and Centaur or 
ECi demonstrated varying agreement, with slopes ranging 
from 0.507 to 1.118, intercepts ranging from -1.689 to 1.512, 
and correlation coefficients (r) ranging from 0.806 to 0.995 
(Table 2). The results from the CEA measured by DxI 
showed the highest degree of agreement with those mea-
sured by Centaur (slope=0.910, r=0.995). CA 15-3 levels 
were poorly agreed upon between DxI and ECi, with a 
slope of 0.507 and correlation coefficients of 0.806. The re-
sults of the samples for all five assays were classified as 
normal or elevated, and the analytic concordance for each 
633.45 to 5.55 kU/L for CA 15-3, from 1752.53 to 7.68 kU/L 
for CA 125, and from 1389.73 to 0.80 kU/L for CA 19-9. 
The results from DxI showed excellent linear responses in 
measuring the concentrations of the five tumor markers (Fig. 
1). The linear fits for all five tumor markers tested were ac-
cepted statistically at the level of p<0.05 (where x is expect-
ed values and y is observed means, y=1.017x-15.855, 
R2=0.9991, F=4648 for AFP; y=1.001x+6.289, R2=0.9997, 
F=15846 for CEA; y=1.000x+5.342, R2=0.9994, F=6445 
for CA 125; y=1.022x-0.080, R2=0.9983, F=2285 for CA 
15-3; y=1.015x-8.488, R2=0.9995, F=7459 for CA 19-9; 
p<0.001 for all).
Fig. 1. Linearity of the five tumor marker assays performed by UniCelTM DxI 800. The observed mean tumor marker levels showed excellent linear responses 
to the expected values (p<0.001). (A) The linearity range of the CEA assay was from 0.80 to 951.41 μg/L (R2=0.9997). (B) The AFP assay was linear in the range 
between 1.86 and 2092.91 μg/L (R2=0.9991). (C) The CA 15-3 assay showed linear responses to the expected concentrations in the range of 5.55 to 633.45 kU/L 
(R2=0.9983). (D) The CA 125 assay was verified to be linear at the concentrations between 7.68 and 1752.53 kU/L (R2=0.9994). (E) Linearity of the CA 19-9 assay 
was validated in the range of 0.80 to 1389.73 kU/L (R2=0.9995). CEA, carcinoembryonic antigen; AFP, alpha-fetoprotein; CA, carbohydrate antigen.
Table 2. Parameters of Passing and Bablok Regression between UniCelTM DxI 800 and the Other Systems
Markers* Comparative system Slope (95% CI) Intercept (95% CI)* Correlation coefficient (r)
CEA Advia CentaurTM 0.910 (0.883 to 0.947)  -0.240 (-0.362 to -0.171) 0.995
AFP Advia CentaurTM 0.766 (0.745 to 0.780)  -0.624 (-0.784 to -0.493) 0.994
CA 15-3 VitrosTM ECi 0.507 (0.474 to 0.545) 1.052 (0.591 to 1.458) 0.806
CA 125 Advia CentaurTM 1.118 (1.091 to 1.164)  -1.689 (-2.394 to -1.331) 0.986
CA 19-9 VitrosTM ECi 0.606 (0.569 to 0.645) 1.512 (0.930 to 2.093) 0.971
CI, confidence interval; CEA, carcinoembryonic antigen; AFP, alpha-fetoprotein; CA, carbohydrate antigen.
*Units are µg/L for CEA and AFP, and kU/L for CA 15-3, CA 125, and CA 19-9. 
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tice, tumor markers are useful in evaluating the progression 
of disease status after surgical or cytotoxic therapies have 
been undertaken and in monitoring subsequent treatment 
modalities.1-7,20 Therefore, precise and accurate assays for 
tumor markers are important in the management of patients 
with cancer.
In this study, we assessed the analytical performances of 
the UniCelTM DxI 800 Access Immunoassay System in mea-
suring tumor marker concentrations. The results on the lin-
earity and imprecision of the assays by DxI were highly ac-
ceptable and in accordance with previous reports.12,14-16,21-23 
In addition, we compared the results from DxI for CEA, 
AFP, and CA 125 with those measured by Centaur, and for 
CA 15-3 and CA 19-9 with those measured by ECi, as our 
laboratory currently uses Centaur and ECi, which were in-
tended to be replaced with DxI, for assaying these respec-
tive tumor markers. The extensive differences between ana-
lyzer systems, which are shown in Fig. 2, could be caused 
by different antibodies utilized by the assaying systems or 
by unique circumstances of the samples.2,12,24 In the case of 
CA 15-3, the respective assays utilize different CA 15-3 
MAbs as the Ma552 antibody targeted epitope in the GVT-
SAPDTRAPP region on the MUC1 glycoprotein core, and 
the DF3M antibody targeted epitope Ma695 on a carbohy-
tumor marker was assessed using the cut-offs recommend-
ed by the manufacturers (Table 3). The overall concordance 
rates between DxI and Centaur or ECi ranged from 84.5% 
to 97.0%.
When the results for each marker were analyzed using 
difference plots (Fig. 2), CEA and CA 125 concentrations 
showed mean differences of 30 or less between DxI and 
Centaur, and CA 15-3 levels demonstrated a mean differ-
ence of -27.59 kU/L between DxI and ECi. The results of 
CA 19-9 measured by ECi and AFP measured by Centaur 
exhibited large mean differences of -209.59 kU/L and 
-145.39 μg/L, respectively, from those measured by DxI.
DISCUSSION
For many malignancies, serum tumor markers play impor-
tant roles in patient management. Tumor markers are the 
biochemical or immunological indicators of differentiating 
clinical status in patients with malignancies. Many well-
known markers can be elevated in noncancerous conditions, 
and although the presence of tumor markers is not diagnos-
tic of cancer, it is thought that blood levels of tumor markers 
reflect tumor activity and the size of a mass. In clinical prac-
Table 3. Analytic Concordance between UniCelTM DxI 800 and the Other Analyzers
Comparative assays
UniCelTM DxI 800 Overall concordance with 
UniCelTM DxI 800 (%)≥Cut-off* <Cut-off* Total
CEA (Advia CentaurTM) 97.0 
    ≥5 μg/L 94     6 100
    <5 μg/L   0 100 100
    Total 94 106 200
AFP (Advia CentaurTM) 95.0 
    ≥7 μg/L 90   10 100
    <7 μg/L   0 100 100
    Total 90 110 200
CA 15-3 (VitrosTM ECi) 84.5 
    ≥35 kU/L 69   31 100
    <35 kU/L   0 100 100
    Total 69 131 200
CA 125 (Advia CentaurTM) 96.0 
    ≥35 kU/L 94     6 100
    <35 kU/L   2   98 100
    Total 96 104 200
CA 19-9 (VitrosTM ECi) 89.5 
    ≥37 kU/L 81   19 100
    <37 kU/L   2   98 100
    Total 83 117 200
CEA, carcinoembryonic antigen; AFP, alpha-fetoprotein; CA, carbohydrate antigen.
*CEA, 5.0 μg/L; AFP, 7.4 μg/L; CA 15-3, 31.3 kU/L; CA 125, 35.0 kU/L; CA 19-9, 35.0 kU/L.
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Fig. 2. Comparison of the results of five tumor markers measured by the UniCelTM DxI 800 with those measured by other instruments using Bland and Altman 
difference plots. The solid line indicates the mean difference between the methods, and the dashed lines indicate the upper and lower 95% confidence lim-
its of the difference between the methods. (A) The mean difference of CEA was 5.62 μg/L [95% confidence interval (CI), -6.53 to 17.77 μg/L]. (B) The mean dif-
ference of AFP was -145.39 μg/L (95% CI, -220.47 to -70.32 μg/L). (C) The mean difference of CA 15-3 was -27.59 kU/L (95% CI, -36.24 to -18.94 kU/L). (D) The 
mean difference of CA 125 was 26.73 kU/L (95% CI, 3.72 to 49.74 kU/L). (E) The mean difference of CA 19-9 was -209.59 kU/L (95% CI, -312.58 to -106.60 kU/L). 
CEA, carcinoembryonic antigen; AFP, alpha-fetoprotein; CA, carbohydrate antigen.
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veloped by different manufacturers, discrepant results re-
main among analytical methods. These differences may re-
sult from the application of different antibodies by different 
assays and suppliers. Additional efforts to standardize tu-
mor marker assays are greatly necessitated, and the estab-
lishment of reliable reference materials and methods are 
also needed. The substantial differences between methods 
also indicate that the redetermination of baselines and cut-
off levels is necessary when replacing analyzers and meth-
ods for measuring tumor marker assays.
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by DxI and the other systems seem to be due to the high an-
tigen levels of the samples tested in our study.
In addition, CA 15-3 and CA 19-9 measured by DxI and 
ECi in this study showed relatively lower concordance rates 
and correlation coefficients among the results between the 
two analyzers, and the results for CEA, AFP, and CA 125 
measured by DxI were more comparable to those by Centaur. 
The concordance between assay systems can vary according 
to the evaluated tumor markers and researchers.12,15,16,21,22 
Therefore, even though the results, on average, agreed fair-
ly well across the assays, when replacing tumor marker as-
says for clinical use, parallel tests by old and new methods 
are recommended to establish a new baseline in the man-
agement of patients. 
These days, the incidence and prevalence of tumors are 
increasing due to advances in the technology of cancer de-
tection and longer average life expectancies. Accordingly, 
the number of specimens for tumor marker testing has in-
creased, and in the case of our laboratory, more than 18000 
tumor marker tests are performed monthly. Because of this 
assay workload, one instrument cannot sufficiently analyze 
all five tumor markers, presently, and we have adopted the 
use of more than four immunoassay analyzers in our lab, 
including those compared in this study. From sample aspi-
ration to results, the incubation times are 20 minutes for 
AFP and CEA and 50 minutes for CA 125 with the Centaur 
system, and 45 minutes for CA 19-9 and 50 minutes for CA 
15-3 with the ECi system on average. Compared with those 
two analyzers, DxI has similar incubation times as follows: 
20 minutes for AFP and CEA, 45 minutes for CA 19-9, and 
50 minutes in CA 125 and CA 15-3. However, quicker re-
sults may be derived using the DxI system, which can ana-
lyze all five tumor markers and load 120 samples at once.
In conclusion, our study demonstrated that the UniCelTM 
DxI 800 system has high analytical performance. In spite of 
efforts to harmonize the results from different analyzers de-
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